Sanofi (NYSE:SNY)‘s stock had its “buy” rating reissued by Leerink Swann in a report released on Sunday.

A number of other brokerages also recently weighed in on SNY. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Jefferies Group restated a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Citigroup Inc. restated a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. TheStreet upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Finally, BNP Paribas upgraded Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $60.50.

Analyst Recommendations for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) opened at 38.53 on Friday. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88. The stock has a market capitalization of $99.18 billion, a price-to-earnings ratio of 21.36 and a beta of 0.98. The firm’s 50-day moving average is $38.79 and its 200-day moving average is $40.45.

Hedge funds have recently made changes to their positions in the stock. Dodge & Cox raised its stake in shares of Sanofi by 3.0% in the second quarter. Dodge & Cox now owns 55,155,913 shares of the company’s stock valued at $2,308,275,000 after buying an additional 1,625,784 shares during the period. Fisher Asset Management LLC raised its stake in shares of Sanofi by 0.7% in the second quarter. Fisher Asset Management LLC now owns 13,638,183 shares of the company’s stock worth $564,894,000 after buying an additional 91,233 shares during the period. Hotchkis & Wiley Capital Management LLC raised its stake in shares of Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock worth $478,434,000 after buying an additional 1,267,118 shares during the period. Boston Partners raised its stake in shares of Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock worth $309,774,000 after buying an additional 7,330,168 shares during the period. Finally, Brandes Investment Partners LP raised its stake in shares of Sanofi by 1.2% in the second quarter. Brandes Investment Partners LP now owns 3,600,731 shares of the company’s stock worth $150,691,000 after buying an additional 44,010 shares during the period. Institutional investors and hedge funds own 9.42% of the company’s stock.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.